332 related articles for article (PubMed ID: 17890246)
1. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure.
Othersen JB; Maize JC; Woolson RF; Budisavljevic MN
Nephrol Dial Transplant; 2007 Nov; 22(11):3179-85. PubMed ID: 17890246
[TBL] [Abstract][Full Text] [Related]
2. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
[TBL] [Abstract][Full Text] [Related]
3. An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital.
Marckmann P
Eur J Radiol; 2008 May; 66(2):187-90. PubMed ID: 18328659
[TBL] [Abstract][Full Text] [Related]
4. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.
Marckmann P; Skov L; Rossen K; Dupont A; Damholt MB; Heaf JG; Thomsen HS
J Am Soc Nephrol; 2006 Sep; 17(9):2359-62. PubMed ID: 16885403
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure.
Todd DJ; Kagan A; Chibnik LB; Kay J
Arthritis Rheum; 2007 Oct; 56(10):3433-41. PubMed ID: 17907148
[TBL] [Abstract][Full Text] [Related]
6. Gadolinium-associated nephrogenic systemic fibrosis.
Schlaudecker JD; Bernheisel CR
Am Fam Physician; 2009 Oct; 80(7):711-4. PubMed ID: 19817341
[TBL] [Abstract][Full Text] [Related]
7. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent.
Rydahl C; Thomsen HS; Marckmann P
Invest Radiol; 2008 Feb; 43(2):141-4. PubMed ID: 18197066
[TBL] [Abstract][Full Text] [Related]
8. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.
Kallen AJ; Jhung MA; Cheng S; Hess T; Turabelidze G; Abramova L; Arduino M; Guarner J; Pollack B; Saab G; Patel PR
Am J Kidney Dis; 2008 Jun; 51(6):966-75. PubMed ID: 18501784
[TBL] [Abstract][Full Text] [Related]
9. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis?
Boyd AS; Sanyal S; Abraham JL
J Am Acad Dermatol; 2010 Feb; 62(2):337-42. PubMed ID: 19939504
[TBL] [Abstract][Full Text] [Related]
10. Nephrogenic systemic fibrosis: a report of 29 cases.
Shabana WM; Cohan RH; Ellis JH; Hussain HK; Francis IR; Su LD; Mukherji SK; Swartz RD
AJR Am J Roentgenol; 2008 Mar; 190(3):736-41. PubMed ID: 18287446
[TBL] [Abstract][Full Text] [Related]
11. Gadolinium-associated nephrogenic systemic fibrosis: the need for nephrologists' awareness.
Canavese C; Mereu MC; Aime S; Lazzarich E; Fenoglio R; Quaglia M; Stratta P
J Nephrol; 2008; 21(3):324-36. PubMed ID: 18587720
[TBL] [Abstract][Full Text] [Related]
12. [Nephrogenic systemic fibrosis: another problem for patients with chronic renal failure].
Michelet PR; Chopard CS; Martin PY; Vallée JP
Rev Med Suisse; 2008 Mar; 4(147):576-8, 580. PubMed ID: 18402015
[TBL] [Abstract][Full Text] [Related]
13. Nephrogenic systemic fibrosis in advanced chronic kidney disease: a single hospital's experience in Taiwan.
Chen W; Huang SL; Huang CS; Tsai MC; Lai HM; Lui CC; Eng HL; Chang HW; Lee CH; Chuang FR
Eur J Dermatol; 2009; 19(1):44-9. PubMed ID: 19059824
[TBL] [Abstract][Full Text] [Related]
14. Nephrogenic systemic fibrosis: a clinicopathologic study of six cases.
Pryor JG; Poggioli G; Galaria N; Gust A; Robison J; Samie F; Hanjani NM; Scott GA
J Am Acad Dermatol; 2007 Jul; 57(1):105-11. PubMed ID: 17412451
[TBL] [Abstract][Full Text] [Related]
15. A follow-up of four cases of nephrogenic systemic fibrosis: is gadolinium the specific trigger?
Singh M; Davenport A; Clatworthy I; Lewin J; Deroide F; Hubbard V; Rustin MH
Br J Dermatol; 2008 Jun; 158(6):1358-62. PubMed ID: 18363754
[TBL] [Abstract][Full Text] [Related]
16. The impact of NSF on the care of patients with kidney disease.
Abu-Alfa A
J Am Coll Radiol; 2008 Jan; 5(1):45-52. PubMed ID: 18180009
[TBL] [Abstract][Full Text] [Related]
17. Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure.
Grobner T; Prischl FC
Semin Dial; 2008; 21(2):135-9. PubMed ID: 18226001
[TBL] [Abstract][Full Text] [Related]
18. Nephrogenic systemic fibrosis: an overview.
Cowper SE
J Am Coll Radiol; 2008 Jan; 5(1):23-8. PubMed ID: 18180005
[TBL] [Abstract][Full Text] [Related]
19. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis.
Abraham JL; Thakral C; Skov L; Rossen K; Marckmann P
Br J Dermatol; 2008 Feb; 158(2):273-80. PubMed ID: 18067485
[TBL] [Abstract][Full Text] [Related]
20. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy.
Kribben A; Witzke O; Hillen U; Barkhausen J; Daul AE; Erbel R
J Am Coll Cardiol; 2009 May; 53(18):1621-8. PubMed ID: 19406336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
